The Effectiveness of Mycophenolate Mofetil in Refractory Pyoderma Gangrenosum

Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS

“…Since mycophenolate mofetil was known to be useful in pyoderma gangrenosum [77], it was as an effective steroid-sparing agent for this patient [9].…”

Mechanism of Action and Emerging Role of Immune Response Modifier Therapy in Dermatologic Conditions

“…116,117 Oral mycophenolate mofetil is somewhat efficacious in the treatment of psoriasis, 118,119 but is more useful in other conditions such as atopic dermatitis, 120 immunobullous diseases, 5,121 eczema, 122 lichen planus, 123 and pyoderma gangrenosum. 124 Overall, mycophenolate demonstrates a favorable safety profile for a systemic immunosuppressant. 115 Theoretical risks that may be associated with mycophenolate therapy include the development of malignancy, neutropenia, and infection.…”

Treatment of Linear IgA Bullous Dermatosis of Childhood With Mycophenolate Mofetil

“…26 The recommended dosage, monitoring regimen, and exact role of mycophenolate mofetil in the treatment of autoimmune and inflammatory cutaneous diseases remain anecdotal. Reports of mycophenolate mofetil being used in the treatment of skin disease have been published for psoriasis, 18,27,28 bullous pemphigoid, [28][29][30][31] pemphigus vulgaris, 28,29,32 dyshidrotic eczema, 33 arthritis, 34 atopic dermatitis, [35][36][37][38] and pyoderma gangrenosum 39,40 in adults. These patients typically received doses between 2 and 3 g/d.…”